Edition:
India

Agenus Says Presents Results From Two Cervical Cancer Trials At ESMO


Friday, 18 Sep 2020 

Sept 18 (Reuters) - Agenus Inc ::AGENUS PRESENTS RESULTS FROM TWO LARGE CERVICAL CANCER TRIALS AT ESMO.AGENUS INC - 160 PATIENT BALSTILIMAB (PD-1) MONOTHERAPY TRIAL ACHIEVES RESPONSE RATES OF 14% IN ALL TREATED PATIENTS AND 19% IN PD-L1 POSITIVE PATIENTS.AGENUS -155 PATIENT BALSTILIMAB (PD-1) + ZALIFRELIMAB COMBINATION TRIAL ACHIEVES RESPONSE RATES OF 22% IN ALL PATIENTS&27% IN PD-L1 POSITIVE PATIENTS.AGENUS INC - BOTH TRIALS CONDUCTED IN PATIENTS WITH RECURRENT/METASTATIC CERVICAL CANCER.AGENUS INC - THESE TRIALS SHOW THAT BALSTILIMAB AND ZALIFRELIMAB MAY PRESENT MEANINGFUL NEW THERAPIES FOR PATIENTS WITH CERVICAL CANCER.